Transcriptome-wide N6-methyladenosine methylation profile of atherosclerosis in mice

• DOI: 10.1186/s12864-023-09878-1
• Publication Date: 2023-12-15T10:06:38Z
• Authors: Xinbin Zheng; Bo Zhou; Yuzhen Li; Hengren Zhong; Zhengxin Huang; Minhua Gu
• Keywords: N6-Methyladenosine; Demethylase; RNA methylation; Methylated DNA immunoprecipitation

Atherosclerosis (AS) is a critical pathological event during the progression of cardiovascular diseases. It exhibits fibrofatty lesions on arterial wall and lacks effective treatment. N6-methyladenosine (m6A) most common modification eukaryotic RNA plays an important role in regulating development However, m6A AS remains largely unknown. Therefore, this study, we explored transcriptome distribution its potential mechanism.Methylation Quantification Kit was used to detect global levels aorta mice. Western blot analyze protein level methyltransferases. Methylated immunoprecipitation with next-generation sequencing (MeRIP-seq) (RNA-seq) were obtain first range analysis methylene map mice, followed by bioinformatics analysis. qRT-PCR MeRIP-qRT-PCR measure mRNA target genes.The methyltransferase METTL3 significantly increased demethylase ALKBH5 decreased. Through MeRIP-seq, obtained methylation maps control In total, 26,918 peaks associated 13,744 genes detected group, whereas 26,157 13,283 group. Peaks mainly appeared coding sequence (CDS) regions close stop codon RRACH motif. Moreover, functional enrichment demonstrated that m6A-containing enriched AS-relevant pathways. Interestingly, negative correlation between abundance gene expression found through integrated MeRIP-seq RNA-seq data. Among m6A-modified genes, hypo-methylated but up-regulated (hypo-up) Fabp5 may be biomarker AS.Our study provides transcriptome-wide for time determine association progression. Our lays foundation further exploring pathogenesis new direction treatment AS.